(株)Veritas In Silico

2026/07/15 Updated
Market Cap: $17.1M (¥2.8B)
Stock Price: $2.64 (¥428)
Exchange Rate: 1 USD = ¥162.07

Stock Price Chart

2026/07/15 Updated
0.00
PER (Price Earnings Ratio)
vs Industry Avg: -9.6
1.56
PBR (Price to Book Ratio)
vs Industry Avg: +0.3
0.00%
Dividend Yield
vs Industry Avg: -2.95%

Price Trend

2026/07/15 Updated
Short-term
5-Day MA
+0.38%
Near-term
25-Day MA
+0.80%
Mid-term
75-Day MA
-2.47%
Long-term
200-Day MA
-13.96%

Price & Trading Details

2026/07/15 Updated

PRICE

Previous Close ¥417
Open ¥417
High ¥436
Low ¥417
Close ¥428

TRADING

Volume 8,100
Average Volume 16,711
Turnover ¥3,466,800
Min. Purchase ¥42,800

Shareholder Composition

Updated 2026/07/01
50.2%
Insider Holdings
14.2%
Institutional
35.6%
Public Float
3
Institutional Holders
Insider Holdings 50.2%
Institutional 14.2%
Public Float 35.6%

Financial Performance

2026/07/12 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2022 2023 2024 2025
Income Statement
Revenue ¥179M ¥360M ¥195M ¥91M
Gross Profit - - - -
Operating Income -¥139M ¥38M -¥213M -¥397M
Pretax Income -¥139M ¥38M -¥213M -¥397M
Net Income -¥141M ¥33M -¥236M -¥426M
EPS -¥25.70 ¥6.01 -¥37.11 -
Operating Margin -77.69% 10.44% -109.35% -435.32%
Balance Sheet
Total Assets ¥1,599M ¥1,656M ¥2,249M ¥1,885M
Total Equity ¥1,543M ¥1,576M ¥2,210M ¥1,784M
Total Liabilities ¥56M ¥80M ¥39M ¥101M
Cash ¥1,484M ¥1,549M ¥2,173M ¥1,825M
Interest-bearing Debt - - - -
Equity Ratio 96.50% 95.17% 98.25% 94.64%
D/E Ratio 0.00 0.00 0.00 0.00
Cash Flow
Operating CF -¥149M ¥69M -¥218M -¥299M
Investing CF -¥56M -¥2M -¥2,006M ¥451M
Financing CF - -¥2M ¥848M -
Free CF -¥204M ¥67M -¥224M -¥331M
Efficiency
ROE -9.17% 2.10% -10.70% -23.86%
ROA -8.84% 2.00% -10.51% -22.58%

Latest IR Information

  • No IR information found for this company.

    Searched stock code: 130A

Company Information

Japanese Name (株)Veritas In Silico
Stock Code 130A.T (JPX)
Sector / Industry Healthcare / Biotechnology
Employees 19

About

Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has commercialization agreement with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan.

Data provided by Yahoo Finance